董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yehia Hashad | 男 | Director | 55 | 11.72万美元 | 未持股 | 2022-10-21 |
| James A. Robinson | 男 | Director | 53 | 6.91万美元 | 未持股 | 2022-10-21 |
| Anne VanLent | 女 | Director | 74 | 7.92万美元 | 未持股 | 2022-10-21 |
| William Aliski | 男 | Director | 75 | 7.82万美元 | 未持股 | 2022-10-21 |
| Susan B. Washer | 女 | President, Chief Executive Officer and Director | 61 | 147.36万美元 | 未持股 | 2022-10-21 |
| Scott Koenig | 男 | Chairman of the Board | 70 | 10.15万美元 | 未持股 | 2022-10-21 |
| Ed Hurwitz | 男 | Director | 58 | 6.52万美元 | 未持股 | 2022-10-21 |
| James Rosen | 男 | Director | 53 | 7.23万美元 | 未持股 | 2022-10-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen Potter | 男 | Vice President and Chief Business Officer | 66 | 68.72万美元 | 未持股 | 2022-10-21 |
| Susan Schneider | 女 | Chief Medical Officer | 64 | 83.26万美元 | 未持股 | 2022-10-21 |
| Hope D'Oyley Gay | 女 | General Counsel | 53 | 未披露 | 未持股 | 2022-10-21 |
| Abraham Scaria | 男 | Chief Scientific Officer | 63 | 未披露 | 未持股 | 2022-10-21 |
| Jonathan I. Lieber | 男 | Chief Financial Officer | 53 | 100.41万美元 | 未持股 | 2022-10-21 |
| Susan B. Washer | 女 | President, Chief Executive Officer and Director | 61 | 147.36万美元 | 未持股 | 2022-10-21 |
董事简历
中英对照 | 中文 | 英文- Yehia Hashad
-
Yehia Hashad自2022年1月31日起担任公司研发执行副总裁兼首席医疗官。Hashad博士曾于2020年5月至2021年8月担任艾伯维公司Allergan Aesthetics的高级副总裁兼研发主管。在艾尔建收购艾伯维之前，从2010年到2020年5月，Hashad博士在副总裁担任过多个研发执行职位，包括高级副总裁0,2019年4月至2020年5月担任全球临床开发主管副总裁和眼科临床开发全球主管，2017年5月至2020年5月任皮肤科和医学美学，2013年9月至2019年4月任眼科和视网膜治疗领域副总裁兼全球负责人。从2005年到2010年，Hashad博士在诺华制药公司担任职务，担任与年龄相关的黄斑变性相关治疗的全球项目医学总监。在此之前，从1996年到2005年，Hashad博士在T3A Pharma Group担任过多个职位。Hashad博士在开罗大学获得医学学位和医学和外科眼科理学硕士学位，并在法国欧洲工商管理学院获得商业学位。他目前在Applied Genetic Technologies Corporation的董事会任职，该公司是一家上市的临床阶段生物技术公司。他之前曾在青光眼研究基金会和全国眼科和视力研究联盟的董事会任职，并担任加州大学欧文分校研究中心的董事会顾问。
Yehia Hashad, M.D. has served as a member of Applied Genetic Technologies Corporation's board of directors since August 2021. Since February 2022 Dr. Hashad has served as Executive Vice President R&D and Chief Medical of Bausch + Lomb, a health products company. Dr. Hashad worked at Allergan plc acquired by Abbvie Inc. in 2019 a pharmaceutical company, from 2010 through January 2022 serving most recently as Senior Vice President & Global Head R&D Allergan Aesthetics since 2019 and Vice President & Global Head Clinical Development Ophthalmology, Dermatology and Medical Aesthetics since 2017. Prior to that, Dr. Hashad served in various medical director roles at Novartis AG, a publicly-traded pharmaceutical company, from 2005 to 2010. Dr. Hashad has served as a member of the executive board for the University of California Irvine research unit since 2017. He previously served as a member of the Board of the Glaucoma Research Foundation from 2013 to 2017 and a member of the Board of the National Alliance of Vision and Eye Research from 2014 to 2019. Dr. Hashad holds an M.B.Bch. in Medical and Surgical Sciences and an M.Sc. in Medical and Surgical Ophthalmology from the University of Cairo, Egypt. - Yehia Hashad自2022年1月31日起担任公司研发执行副总裁兼首席医疗官。Hashad博士曾于2020年5月至2021年8月担任艾伯维公司Allergan Aesthetics的高级副总裁兼研发主管。在艾尔建收购艾伯维之前，从2010年到2020年5月，Hashad博士在副总裁担任过多个研发执行职位，包括高级副总裁0,2019年4月至2020年5月担任全球临床开发主管副总裁和眼科临床开发全球主管，2017年5月至2020年5月任皮肤科和医学美学，2013年9月至2019年4月任眼科和视网膜治疗领域副总裁兼全球负责人。从2005年到2010年，Hashad博士在诺华制药公司担任职务，担任与年龄相关的黄斑变性相关治疗的全球项目医学总监。在此之前，从1996年到2005年，Hashad博士在T3A Pharma Group担任过多个职位。Hashad博士在开罗大学获得医学学位和医学和外科眼科理学硕士学位，并在法国欧洲工商管理学院获得商业学位。他目前在Applied Genetic Technologies Corporation的董事会任职，该公司是一家上市的临床阶段生物技术公司。他之前曾在青光眼研究基金会和全国眼科和视力研究联盟的董事会任职，并担任加州大学欧文分校研究中心的董事会顾问。
- Yehia Hashad, M.D. has served as a member of Applied Genetic Technologies Corporation's board of directors since August 2021. Since February 2022 Dr. Hashad has served as Executive Vice President R&D and Chief Medical of Bausch + Lomb, a health products company. Dr. Hashad worked at Allergan plc acquired by Abbvie Inc. in 2019 a pharmaceutical company, from 2010 through January 2022 serving most recently as Senior Vice President & Global Head R&D Allergan Aesthetics since 2019 and Vice President & Global Head Clinical Development Ophthalmology, Dermatology and Medical Aesthetics since 2017. Prior to that, Dr. Hashad served in various medical director roles at Novartis AG, a publicly-traded pharmaceutical company, from 2005 to 2010. Dr. Hashad has served as a member of the executive board for the University of California Irvine research unit since 2017. He previously served as a member of the Board of the Glaucoma Research Foundation from 2013 to 2017 and a member of the Board of the National Alliance of Vision and Eye Research from 2014 to 2019. Dr. Hashad holds an M.B.Bch. in Medical and Surgical Sciences and an M.Sc. in Medical and Surgical Ophthalmology from the University of Cairo, Egypt.
- James A. Robinson
-
James A. Robinson自2021年11月起担任Applied Genetic Technologies Corporation董事会成员。Robinson先生自2020年3月起担任Urovant Sciences Ltd.的首席执行官，该公司是一家专注于开发泌尿系统疾病新疗法的全球生物制药公司，并自2019年3月起担任其董事会成员。2019年4月至2020年3月，Robinson先生担任Paragon Biosciences总裁兼首席运营官，Paragon Biosciences是一家生命科学创新者，致力于创建、投资和建设生物科学公司，负责监督Paragon的运营。Robinson先生曾于2018年3月至2019年4月担任Alkermes, Inc.的总裁兼首席运营官，该公司是一家开发神经科学和肿瘤学领域创新药物的全球生物制药公司。在加入Alkermes, Inc.之前，Robinson先生在制药公司Astellas U.S. LLC工作了超过12年，最近一次是在2016年3月至2018年3月期间担任美洲业务总裁。在此之前，他于2013年4月至2018年3月担任安斯泰来制药Applied Genetic Technologies Corporation总裁。在加入安斯泰来之前，Robinson先生在制药商Schering-Plough制药公司工作了13年，他的最后一个职位是肝炎销售和管理式护理副总裁。Robinson先生之前曾在Neos治疗和芝加哥植物园的董事会任职，并且是Matter的创始成员。此前，Robinson先生曾在美国药物研究和制造商董事会任职，并担任PhRMA州委员会主席。罗宾逊先生获得了学士学位来自德保罗大学。
James A. Robinson has served as a member of Applied Genetic Technologies Corporation's board of directors since November 2021. Mr. Robinson has served as Chief Executive Officer of Urovant Sciences Ltd., a global biopharmaceutical company focused on developing novel therapies for urologic conditions, since March 2020 and as a member of its board of directors since March 2019. From April 2019 to March 2020 Mr. Robinson held the position of President and Chief Operating Officer at Paragon Biosciences, a life science innovator that creates, invests in and builds bioscience companies, where he oversaw Paragon’s operations. Mr. Robinson previously served as President and Chief Operating Officer of Alkermes, Inc., a global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology, from March 2018 to April 2019. Prior to Alkermes, Inc., Mr. Robinson spent over twelve years at Astellas U.S. LLC, a pharmaceutical company, most recently as President, Americas Operations from March 2016 to March 2018. Prior to that, he was President of Astellas Pharma Applied Genetic Technologies Corporation from April 2013 until March 2018. Prior to Astellas, Mr. Robinson spent thirteen years at Schering-Plough Pharmaceuticals, a pharmaceutical manufacturer, where his last role was Vice President, Hepatitis Sales and Managed Care. Mr. Robinson previously served on the board of directors for Neos Therapeutics and the Chicago Botanic Garden and is a founding member of MATTER. Previously, Mr. Robinson served on the board of directors of Pharmaceutical Research and Manufacturers of America, or PhRMA, and served as Chairman of PHRMA’s State Committee. Mr. Robinson received a B.S. from DePaul University. - James A. Robinson自2021年11月起担任Applied Genetic Technologies Corporation董事会成员。Robinson先生自2020年3月起担任Urovant Sciences Ltd.的首席执行官，该公司是一家专注于开发泌尿系统疾病新疗法的全球生物制药公司，并自2019年3月起担任其董事会成员。2019年4月至2020年3月，Robinson先生担任Paragon Biosciences总裁兼首席运营官，Paragon Biosciences是一家生命科学创新者，致力于创建、投资和建设生物科学公司，负责监督Paragon的运营。Robinson先生曾于2018年3月至2019年4月担任Alkermes, Inc.的总裁兼首席运营官，该公司是一家开发神经科学和肿瘤学领域创新药物的全球生物制药公司。在加入Alkermes, Inc.之前，Robinson先生在制药公司Astellas U.S. LLC工作了超过12年，最近一次是在2016年3月至2018年3月期间担任美洲业务总裁。在此之前，他于2013年4月至2018年3月担任安斯泰来制药Applied Genetic Technologies Corporation总裁。在加入安斯泰来之前，Robinson先生在制药商Schering-Plough制药公司工作了13年，他的最后一个职位是肝炎销售和管理式护理副总裁。Robinson先生之前曾在Neos治疗和芝加哥植物园的董事会任职，并且是Matter的创始成员。此前，Robinson先生曾在美国药物研究和制造商董事会任职，并担任PhRMA州委员会主席。罗宾逊先生获得了学士学位来自德保罗大学。
- James A. Robinson has served as a member of Applied Genetic Technologies Corporation's board of directors since November 2021. Mr. Robinson has served as Chief Executive Officer of Urovant Sciences Ltd., a global biopharmaceutical company focused on developing novel therapies for urologic conditions, since March 2020 and as a member of its board of directors since March 2019. From April 2019 to March 2020 Mr. Robinson held the position of President and Chief Operating Officer at Paragon Biosciences, a life science innovator that creates, invests in and builds bioscience companies, where he oversaw Paragon’s operations. Mr. Robinson previously served as President and Chief Operating Officer of Alkermes, Inc., a global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology, from March 2018 to April 2019. Prior to Alkermes, Inc., Mr. Robinson spent over twelve years at Astellas U.S. LLC, a pharmaceutical company, most recently as President, Americas Operations from March 2016 to March 2018. Prior to that, he was President of Astellas Pharma Applied Genetic Technologies Corporation from April 2013 until March 2018. Prior to Astellas, Mr. Robinson spent thirteen years at Schering-Plough Pharmaceuticals, a pharmaceutical manufacturer, where his last role was Vice President, Hepatitis Sales and Managed Care. Mr. Robinson previously served on the board of directors for Neos Therapeutics and the Chicago Botanic Garden and is a founding member of MATTER. Previously, Mr. Robinson served on the board of directors of Pharmaceutical Research and Manufacturers of America, or PhRMA, and served as Chairman of PHRMA’s State Committee. Mr. Robinson received a B.S. from DePaul University.
- Anne VanLent
-
Anne VanLent，自2013年4月起担任本公司董事。她现任AMV Advisors的总裁，为新兴的成长中的生命科学公司提供企业战略和财务咨询服务。从2002年5月至2008年4月，她担任 Barrier Therapeutics公司的执行副总裁和首席财务官，这是一个开发和销售的皮肤病处方产品的上市制药公司。从1997年7月至2001年10月，她担任Sarnoff Corporation的组合管理部执行副总裁，该司是一个多学科的研究和开发公司。1985-1993年，她担任生物制药上市公司 Liposome Company的高级副总裁兼首席财务官。她目前担任：Biota Pharmaceuticals的董事，审核委员会主席，提名和治理委员会委员；Ocera Therapeutics（原Tranzyme Pharma）的董事，审核委员会主席，提名和治理委员会主席； Onconova Therapeutics的董事，审核委员会主席，薪酬委员会成员，以上公司均是纳斯达克上市医药公司。在过去的五年中，2006-2012年间，她曾担任经营医疗设备的纳斯达克上市公司Integra Life Sciences Holdings的董事，并在该司担任审计委员会主席；纳斯达克上市制药公司Penwest Pharmaceuticals的董事，任期从1997年起直到2010年该司被出售给远藤制药，她于2002-2010年间担任Penwest审核委员会主席。她获得曼荷莲学院物理学学士学位。
Anne VanLent,has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly traded pharmaceutical company, from 2002 through 2008. Ms. VanLent served as a member of the board of directors and audit committee chair of ObsEva SA, a publicly traded biopharmaceutical company, from May 2021 until June 2023. Ms. VanLent also served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation, a publicly traded biotechnology company, from August 2016 until it was acquired by Syncona Limited in December 2022. From May 2013 to June 2020, Ms. VanLent served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.), a publicly traded biotechnology company. Ms. VanLent received a B.A. in physics from Mount Holyoke College. - Anne VanLent，自2013年4月起担任本公司董事。她现任AMV Advisors的总裁，为新兴的成长中的生命科学公司提供企业战略和财务咨询服务。从2002年5月至2008年4月，她担任 Barrier Therapeutics公司的执行副总裁和首席财务官，这是一个开发和销售的皮肤病处方产品的上市制药公司。从1997年7月至2001年10月，她担任Sarnoff Corporation的组合管理部执行副总裁，该司是一个多学科的研究和开发公司。1985-1993年，她担任生物制药上市公司 Liposome Company的高级副总裁兼首席财务官。她目前担任：Biota Pharmaceuticals的董事，审核委员会主席，提名和治理委员会委员；Ocera Therapeutics（原Tranzyme Pharma）的董事，审核委员会主席，提名和治理委员会主席； Onconova Therapeutics的董事，审核委员会主席，薪酬委员会成员，以上公司均是纳斯达克上市医药公司。在过去的五年中，2006-2012年间，她曾担任经营医疗设备的纳斯达克上市公司Integra Life Sciences Holdings的董事，并在该司担任审计委员会主席；纳斯达克上市制药公司Penwest Pharmaceuticals的董事，任期从1997年起直到2010年该司被出售给远藤制药，她于2002-2010年间担任Penwest审核委员会主席。她获得曼荷莲学院物理学学士学位。
- Anne VanLent,has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly traded pharmaceutical company, from 2002 through 2008. Ms. VanLent served as a member of the board of directors and audit committee chair of ObsEva SA, a publicly traded biopharmaceutical company, from May 2021 until June 2023. Ms. VanLent also served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation, a publicly traded biotechnology company, from August 2016 until it was acquired by Syncona Limited in December 2022. From May 2013 to June 2020, Ms. VanLent served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.), a publicly traded biotechnology company. Ms. VanLent received a B.A. in physics from Mount Holyoke College.
- William Aliski
-
William Aliski，自2011年1月以来，一直担任董事会的成员。Aliski先生目前担任Edimer制药公司（一个私营的生物技术公司），和Scioderm公司（一家私人持有的生物制药公司）的董事。从2011年9月到2012年3月，Aliski先生曾担任从事罕见疾病的早期治疗公司的商业顾问，包括Enobia制药公司等。在那之前，从2009年6月到2011年3月，Aliski先生曾担任FoldRx制药公司的高级副总裁和首席商务官，这是一家治疗罕见疾病的公司，现在是辉瑞公司（Pfizer Inc.）的全资子公司；从2008年1月到2009年6月，担任Simon Kucher Partners（全球咨询公司）的一个董事；从2005年12月到2008年1月，担任BioMarin制药公司欧洲区的总经理。Aliski先生持有波士顿学院（Boston College）经济学学士学位和社会规划硕士学位，以及哈佛大学the Kennedy School of Government at Harvard University的公共事务硕士学位。
William Aliski, MPA has served as a member of Applied Genetic Technologies Corporation's board of directors since September 2018. Mr. Aliski has served as a commercial consultant for early-stage orphan disease companies, including Ra Pharmaceuticals, Inc., from October 2016 to March 2017 and from March 2018 to present time, Magenta Pharma, from August 2019 to March 2020 X4 Pharmaceuticals, Inc., from January 2020 to March 2020 Clementia Pharmaceuticals, Inc., from December 2015 to January 2017 OxThera, from January 2015 through April 2015 Prosensa during 2014 Adimab LLC from November 2013 until December 2013 NPS Pharmaceuticals from April 2013 through December 2014 Fidelity Biosciences from August 2012 until December 2012 and Enobia Pharma from September 2011 until March 2012. Before that, Mr. Aliski served as Senior Vice President and Chief Commercial Officer of FoldRx Pharmaceuticals, a rare disease company, from June 2009 until March 2011 as Director of Simon Kucher Partners, a global consulting firm, from January 2008 until June 2009 and as General Manager of BioMarin Europe at BioMarin Pharmaceuticals Inc. from December 2005 until January 2008. Mr. Aliski also served on the board of directors of Ultragenyx Pharmaceutical Inc. from January 2011 until June 2022. Mr. Aliski received a B.S. in Economics and a Master of Social Planning from Boston College and an M.P.A. from the Kennedy School of Government at Harvard University. - William Aliski，自2011年1月以来，一直担任董事会的成员。Aliski先生目前担任Edimer制药公司（一个私营的生物技术公司），和Scioderm公司（一家私人持有的生物制药公司）的董事。从2011年9月到2012年3月，Aliski先生曾担任从事罕见疾病的早期治疗公司的商业顾问，包括Enobia制药公司等。在那之前，从2009年6月到2011年3月，Aliski先生曾担任FoldRx制药公司的高级副总裁和首席商务官，这是一家治疗罕见疾病的公司，现在是辉瑞公司（Pfizer Inc.）的全资子公司；从2008年1月到2009年6月，担任Simon Kucher Partners（全球咨询公司）的一个董事；从2005年12月到2008年1月，担任BioMarin制药公司欧洲区的总经理。Aliski先生持有波士顿学院（Boston College）经济学学士学位和社会规划硕士学位，以及哈佛大学the Kennedy School of Government at Harvard University的公共事务硕士学位。
- William Aliski, MPA has served as a member of Applied Genetic Technologies Corporation's board of directors since September 2018. Mr. Aliski has served as a commercial consultant for early-stage orphan disease companies, including Ra Pharmaceuticals, Inc., from October 2016 to March 2017 and from March 2018 to present time, Magenta Pharma, from August 2019 to March 2020 X4 Pharmaceuticals, Inc., from January 2020 to March 2020 Clementia Pharmaceuticals, Inc., from December 2015 to January 2017 OxThera, from January 2015 through April 2015 Prosensa during 2014 Adimab LLC from November 2013 until December 2013 NPS Pharmaceuticals from April 2013 through December 2014 Fidelity Biosciences from August 2012 until December 2012 and Enobia Pharma from September 2011 until March 2012. Before that, Mr. Aliski served as Senior Vice President and Chief Commercial Officer of FoldRx Pharmaceuticals, a rare disease company, from June 2009 until March 2011 as Director of Simon Kucher Partners, a global consulting firm, from January 2008 until June 2009 and as General Manager of BioMarin Europe at BioMarin Pharmaceuticals Inc. from December 2005 until January 2008. Mr. Aliski also served on the board of directors of Ultragenyx Pharmaceutical Inc. from January 2011 until June 2022. Mr. Aliski received a B.S. in Economics and a Master of Social Planning from Boston College and an M.P.A. from the Kennedy School of Government at Harvard University.
- Susan B. Washer
-
Susan B. Washer，从2002年3月开始担任公司总裁兼CEO，2003年起担任董事。在成为总裁和CEO以前，她于2001年10月至2002年3月间担任公司首席运营官。1996年8月-2001年10月，她任Scenic Productions公司裁兼CEO，该公司是一家专业建筑公司，为娱乐产业提供雕刻、涂漆和建设服务。1994年6月至1996年8月，她担任北佛罗里达技术创新中心创始执行董事，后担任商业顾问， 该公司是一家公私合营机构，为创业公司提供通过佛罗里达州一些大学批准的技术服务。1983年10月至1994年6月，她在雅培公司和礼来制药厂担任过各种研发和药物管理职位。她拥有密歇根州立大学生物化学学士和佛罗里达大学工商管理硕士学位。
Susan B. Washer has served as Applied Genetic Technologies Corporation's President and Chief Executive Officer since March 2002 and as a member of Applied Genetic Technologies Corporation's board of directors since November 2003. Prior to becoming Applied Genetic Technologies Corporation's President and Chief Executive Officer, Ms. Washer served as Applied Genetic Technologies Corporation's Chief Operating Officer from October 2001 to March 2002. From August 1996 to October 2001 Ms. Washer was President and Chief Executive Officer of Scenic Productions Inc., a specialty construction firm providing sculpting, painting and construction services to the entertainment industry. From June 1994 to August 1996 Ms. Washer served as the Founding Executive Director and then Business Advisor for the North Florida Technology Innovation Center, a public-private organization financing and providing services to entrepreneurial companies licensing technology from Florida universities. From October 1983 to June 1994 Ms. Washer served in various research and pharmaceutical management positions with Abbott Laboratories and Eli Lilly and Company. Ms. Washer also served on the board of Histogenics Corporation from April 2018 to September 2019. In addition, Ms. Washer serves on several biotechnology industry related boards and committees, including as an appointed member of the Small Business Capital Formation Advisory Committee for the Securities and Exchange Commission, the Associate Vice President of the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization "BIO", and a member of the Board of Directors of each of BIO and BioFlorida. Ms. Washer received a B.S. in biochemistry from Michigan State University and an M.B.A. from the University of Florida. - Susan B. Washer，从2002年3月开始担任公司总裁兼CEO，2003年起担任董事。在成为总裁和CEO以前，她于2001年10月至2002年3月间担任公司首席运营官。1996年8月-2001年10月，她任Scenic Productions公司裁兼CEO，该公司是一家专业建筑公司，为娱乐产业提供雕刻、涂漆和建设服务。1994年6月至1996年8月，她担任北佛罗里达技术创新中心创始执行董事，后担任商业顾问， 该公司是一家公私合营机构，为创业公司提供通过佛罗里达州一些大学批准的技术服务。1983年10月至1994年6月，她在雅培公司和礼来制药厂担任过各种研发和药物管理职位。她拥有密歇根州立大学生物化学学士和佛罗里达大学工商管理硕士学位。
- Susan B. Washer has served as Applied Genetic Technologies Corporation's President and Chief Executive Officer since March 2002 and as a member of Applied Genetic Technologies Corporation's board of directors since November 2003. Prior to becoming Applied Genetic Technologies Corporation's President and Chief Executive Officer, Ms. Washer served as Applied Genetic Technologies Corporation's Chief Operating Officer from October 2001 to March 2002. From August 1996 to October 2001 Ms. Washer was President and Chief Executive Officer of Scenic Productions Inc., a specialty construction firm providing sculpting, painting and construction services to the entertainment industry. From June 1994 to August 1996 Ms. Washer served as the Founding Executive Director and then Business Advisor for the North Florida Technology Innovation Center, a public-private organization financing and providing services to entrepreneurial companies licensing technology from Florida universities. From October 1983 to June 1994 Ms. Washer served in various research and pharmaceutical management positions with Abbott Laboratories and Eli Lilly and Company. Ms. Washer also served on the board of Histogenics Corporation from April 2018 to September 2019. In addition, Ms. Washer serves on several biotechnology industry related boards and committees, including as an appointed member of the Small Business Capital Formation Advisory Committee for the Securities and Exchange Commission, the Associate Vice President of the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization "BIO", and a member of the Board of Directors of each of BIO and BioFlorida. Ms. Washer received a B.S. in biochemistry from Michigan State University and an M.B.A. from the University of Florida.
- Scott Koenig
-
Scott Koenig，医学博士，自2002年4月起担任Applied Genetic Technologies Corporation董事会成员，自2004年4月起担任Applied Genetic Technologies Corporation董事会主席。Koenig博士自2001年9月起担任上市生物制药公司Macrogenics, Inc.的总裁兼首席执行官和董事，并且是其联合创始人之一。在加入Macrogenics之前，Koenig博士曾担任生物制药公司MedImmune Inc.的研究高级副总裁，在那里他参与了其产品线的选择和成熟。从1984年到1990年，他在美国国立卫生研究院国家过敏和传染病研究所的免疫调节实验室工作，在那里他研究了对逆转录病毒的免疫反应并研究了艾滋病的发病机制。Koenig博士目前在Glycomimetics, Inc.GLYC、国际生物医学Research Alliance和生物技术创新组织的董事会任职。Koenig博士获得了A.B。和博士来自康奈尔大学和休斯顿德克萨斯大学健康科学中心的医学博士。他在宾夕法尼亚大学医院完成了内科住院医师培训，并获得了内科、过敏和免疫学委员会认证。
Scott Koenig, M.D., Ph.D. has served as a member of Applied Genetic Technologies Corporation's board of directors since April 2002 and as chairman of Applied Genetic Technologies Corporation's board of directors since April 2004. Dr. Koenig has served as the President and Chief Executive Officer and a director of MacroGenics, Inc., a publicly traded biopharmaceutical company, since September 2001 and was one of its co-founders. Prior to joining MacroGenics, Dr. Koenig served as Senior Vice President of Research at MedImmune Inc., a biopharmaceutical company, where he participated in the selection and maturation of its product pipeline. From 1984 to 1990 he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, or NIH, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr. Koenig currently serves on the board of directors of each of GlycoMimetics, Inc. GLYC, The International Biomedical Research Alliance, and the Biotechnology Innovation Organization (BIO). Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston. He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, and is board certified in Internal Medicine and Allergy and Immunology. - Scott Koenig，医学博士，自2002年4月起担任Applied Genetic Technologies Corporation董事会成员，自2004年4月起担任Applied Genetic Technologies Corporation董事会主席。Koenig博士自2001年9月起担任上市生物制药公司Macrogenics, Inc.的总裁兼首席执行官和董事，并且是其联合创始人之一。在加入Macrogenics之前，Koenig博士曾担任生物制药公司MedImmune Inc.的研究高级副总裁，在那里他参与了其产品线的选择和成熟。从1984年到1990年，他在美国国立卫生研究院国家过敏和传染病研究所的免疫调节实验室工作，在那里他研究了对逆转录病毒的免疫反应并研究了艾滋病的发病机制。Koenig博士目前在Glycomimetics, Inc.GLYC、国际生物医学Research Alliance和生物技术创新组织的董事会任职。Koenig博士获得了A.B。和博士来自康奈尔大学和休斯顿德克萨斯大学健康科学中心的医学博士。他在宾夕法尼亚大学医院完成了内科住院医师培训，并获得了内科、过敏和免疫学委员会认证。
- Scott Koenig, M.D., Ph.D. has served as a member of Applied Genetic Technologies Corporation's board of directors since April 2002 and as chairman of Applied Genetic Technologies Corporation's board of directors since April 2004. Dr. Koenig has served as the President and Chief Executive Officer and a director of MacroGenics, Inc., a publicly traded biopharmaceutical company, since September 2001 and was one of its co-founders. Prior to joining MacroGenics, Dr. Koenig served as Senior Vice President of Research at MedImmune Inc., a biopharmaceutical company, where he participated in the selection and maturation of its product pipeline. From 1984 to 1990 he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, or NIH, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr. Koenig currently serves on the board of directors of each of GlycoMimetics, Inc. GLYC, The International Biomedical Research Alliance, and the Biotechnology Innovation Organization (BIO). Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston. He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, and is board certified in Internal Medicine and Allergy and Immunology.
- Ed Hurwitz
-
Ed Hurwitz 2012年11月以来，一直担任Applied Genetic Technologies Corporation董事会成员。Hurwitz先生是医疗保健风险投资公司MPM Capital的董事总经理，以及Hurwitz先生创立的咨询和投资咨询公司Precision Bioventures，LLC的董事总经理。从2002年到2014年12月，他担任Alta Partners的董事。Hurwitz先生目前担任Aryalis Therapeutics、Protego Biopharm、Rekindle Therapeutics和BioIntervense，Inc.的Shlomo Kramer，以及Recode Therapeutics（所有私营生物技术公司）的董事会成员。Hurwitz先生还担任Macrogenics公司和Dyne Therapeutics的董事会成员，这两家公司均为上市生物技术公司。在加入Alta之前，Hurwitz先生于1997年至2002年担任Affymetrix的高级副总裁兼首席财务官。1994年至1997年，Hurwitz先生担任Robertson Stephens & Company的生物技术研究分析师，1992年至1994年担任Smith Barney Shearson的生物技术研究分析师。从1990年到1992年，他在Cooley Godward LLP从事商法工作。Hurwitz先生分别获得了加州大学伯克利分校Boalt法学院和哈斯商学院的法学博士学位和工商管理硕士学位。他还拥有学士学位。康奈尔大学分子生物学博士。
Ed Hurwitz has served as a member of Applied Genetic Technologies Corporation's board of directors since November 2012. Mr. Hurwitz is a Managing Director of MPM Capital, a healthcare venture capital firm, and a Managing Director of Precision Bioventures, LLC, a consulting and investment advisory firm founded by Mr. Hurwitz. He was a director at Alta Partners from 2002 through December 2014. Mr. Hurwitz currently serves as Chairman of the board of directors of Aryalis Therapeutics, Protego BioPharm, Rekindle Therapeutics, and BioIntervene, Inc., as well as a board member of Recode Therapeutics, all privately held, biotechnology companies. Mr. Hurwitz also serves as a member of the board of directors of MacroGenics, Inc. and Dyne Therapeutics, each of which is a publicly traded biotechnology company. Prior to joining Alta, Mr. Hurwitz served as Senior Vice President and CFO of Affymetrix from 1997 to 2002. From 1994 to 1997 Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens & Company, and from 1992 to 1994 was a biotechnology research analyst for Smith Barney Shearson. From 1990 to 1992 he practiced commercial law at Cooley Godward LLP. Mr. Hurwitz earned a J.D. and M.B.A. from the University of California, Berkeley's Boalt School of Law and Haas School of Business, respectively. He also holds a B.A. in Molecular Biology from Cornell University. - Ed Hurwitz 2012年11月以来，一直担任Applied Genetic Technologies Corporation董事会成员。Hurwitz先生是医疗保健风险投资公司MPM Capital的董事总经理，以及Hurwitz先生创立的咨询和投资咨询公司Precision Bioventures，LLC的董事总经理。从2002年到2014年12月，他担任Alta Partners的董事。Hurwitz先生目前担任Aryalis Therapeutics、Protego Biopharm、Rekindle Therapeutics和BioIntervense，Inc.的Shlomo Kramer，以及Recode Therapeutics（所有私营生物技术公司）的董事会成员。Hurwitz先生还担任Macrogenics公司和Dyne Therapeutics的董事会成员，这两家公司均为上市生物技术公司。在加入Alta之前，Hurwitz先生于1997年至2002年担任Affymetrix的高级副总裁兼首席财务官。1994年至1997年，Hurwitz先生担任Robertson Stephens & Company的生物技术研究分析师，1992年至1994年担任Smith Barney Shearson的生物技术研究分析师。从1990年到1992年，他在Cooley Godward LLP从事商法工作。Hurwitz先生分别获得了加州大学伯克利分校Boalt法学院和哈斯商学院的法学博士学位和工商管理硕士学位。他还拥有学士学位。康奈尔大学分子生物学博士。
- Ed Hurwitz has served as a member of Applied Genetic Technologies Corporation's board of directors since November 2012. Mr. Hurwitz is a Managing Director of MPM Capital, a healthcare venture capital firm, and a Managing Director of Precision Bioventures, LLC, a consulting and investment advisory firm founded by Mr. Hurwitz. He was a director at Alta Partners from 2002 through December 2014. Mr. Hurwitz currently serves as Chairman of the board of directors of Aryalis Therapeutics, Protego BioPharm, Rekindle Therapeutics, and BioIntervene, Inc., as well as a board member of Recode Therapeutics, all privately held, biotechnology companies. Mr. Hurwitz also serves as a member of the board of directors of MacroGenics, Inc. and Dyne Therapeutics, each of which is a publicly traded biotechnology company. Prior to joining Alta, Mr. Hurwitz served as Senior Vice President and CFO of Affymetrix from 1997 to 2002. From 1994 to 1997 Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens & Company, and from 1992 to 1994 was a biotechnology research analyst for Smith Barney Shearson. From 1990 to 1992 he practiced commercial law at Cooley Godward LLP. Mr. Hurwitz earned a J.D. and M.B.A. from the University of California, Berkeley's Boalt School of Law and Haas School of Business, respectively. He also holds a B.A. in Molecular Biology from Cornell University.
- James Rosen
-
James Rosen自2010年3月以来，一直担任Applied Genetic Technologies Corporation董事会成员；他目前是Readdi，Inc（一家501c（3）公司）的首席执行官，在此之前，他是精密治疗公司Artizan Biosciences的首席执行官。Readdi，Inc.致力于发现和开发用于大流行预防的广谱抗病毒疗法。2015年2月至2016年8月，Rosen先生担任比尔和梅琳达·盖茨基金会风险投资副主任。在此之前，Rosen先生于2007年1月至2014年12月担任风险投资公司Intersouth Partners的合伙人。在加入Intersouth之前，他在医疗保健和生物技术领域的临床、研究和财务职位上工作了15年，包括从2000年到2003年在Brean Murray & Co.担任股票研究分析师，涵盖生物制药、基因组学、仿制药、药物输送和医疗器械公司。罗森先生拥有学士学位。来自杜克大学、北卡罗来纳大学教堂山分校凯南-弗拉格勒商学院的工商管理硕士学位和M.S.P.H。来自北卡罗来纳大学公共卫生学院。
James Rosen has served as a member of Applied Genetic Technologies Corporation's board of directors since March 2010; he is currently CEO of READDI, Inc, a 501c(3) corporation, prior to which he was CEO of Artizan Biosciences, a precision therapeutics company. READDI, Inc. is engaged in the discovery and development of broad-spectrum antiviral therapeutics for pandemic preparedness. From February 2015 through August 2016 Mr. Rosen served as Deputy Director, Venture Investing at the Bill & Melinda Gates Foundation. Prior to that, Mr. Rosen was a partner at Intersouth Partners, a venture capital firm, from January 2007 to December 2014. Prior to joining Intersouth, he spent 15 years in clinical, research and financial positions in the healthcare and biotechnology sectors, including serving as an equity research analyst at Brean Murray & Co., from 2000 to 2003 covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. Mr. Rosen holds a B.A. from Duke University,an M.B.A. from the University of North Carolina-Chapel Hill's Kenan-Flagler School of Business and an M.S.P.H. from the University of North Carolina School of Public Health. - James Rosen自2010年3月以来，一直担任Applied Genetic Technologies Corporation董事会成员；他目前是Readdi，Inc（一家501c（3）公司）的首席执行官，在此之前，他是精密治疗公司Artizan Biosciences的首席执行官。Readdi，Inc.致力于发现和开发用于大流行预防的广谱抗病毒疗法。2015年2月至2016年8月，Rosen先生担任比尔和梅琳达·盖茨基金会风险投资副主任。在此之前，Rosen先生于2007年1月至2014年12月担任风险投资公司Intersouth Partners的合伙人。在加入Intersouth之前，他在医疗保健和生物技术领域的临床、研究和财务职位上工作了15年，包括从2000年到2003年在Brean Murray & Co.担任股票研究分析师，涵盖生物制药、基因组学、仿制药、药物输送和医疗器械公司。罗森先生拥有学士学位。来自杜克大学、北卡罗来纳大学教堂山分校凯南-弗拉格勒商学院的工商管理硕士学位和M.S.P.H。来自北卡罗来纳大学公共卫生学院。
- James Rosen has served as a member of Applied Genetic Technologies Corporation's board of directors since March 2010; he is currently CEO of READDI, Inc, a 501c(3) corporation, prior to which he was CEO of Artizan Biosciences, a precision therapeutics company. READDI, Inc. is engaged in the discovery and development of broad-spectrum antiviral therapeutics for pandemic preparedness. From February 2015 through August 2016 Mr. Rosen served as Deputy Director, Venture Investing at the Bill & Melinda Gates Foundation. Prior to that, Mr. Rosen was a partner at Intersouth Partners, a venture capital firm, from January 2007 to December 2014. Prior to joining Intersouth, he spent 15 years in clinical, research and financial positions in the healthcare and biotechnology sectors, including serving as an equity research analyst at Brean Murray & Co., from 2000 to 2003 covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. Mr. Rosen holds a B.A. from Duke University,an M.B.A. from the University of North Carolina-Chapel Hill's Kenan-Flagler School of Business and an M.S.P.H. from the University of North Carolina School of Public Health.
高管简历
中英对照 | 中文 | 英文- Stephen Potter
Stephen Potter，2015年1月起，担任本公司的副总裁、首席商业官。加入本公司之前，他任职于NeoStem, Inc.，这是基于细胞疗法的开发商；2013年7月至2015年2月，担任其执行副总裁；2013年1月至7月，担任董事。此前，2011年2月至2012年11月，他担任Osiris Therapeutics, Inc.的运营与企业发展高级副总裁，是史上首个获得审批的干细胞药物疗法Prochymal的高级领导团队成员；他还曾负责生物外科业务部门的组建和全面管理，并负责许多职能领域的业务监督，包括制造、人力资源、信息技术、法律、业务开发。2006-2010，他曾担任的Genzyme Corporation企业与业务开发高级副总裁，以及企业与业务开发副总裁；任职于该 公司期间，他曾是全球企业与业务开发团队的高级领导人，提供策略及交易支持，其中曾为公司的许多基因和细胞疗法业务提供支持。他还在下列公司担任过多个职务：DuPont Pharmaceuticals、E.I. Dupont de Nemours and Company, Inc.、Booz Allen & Hamilton。他在University of Massachusetts获得学士学位，在Harvard Business School获得工商管理硕士。
Stephen Potter has served as Applied Genetic Technologies Corporation's Chief Business Officer since February 2015. Prior to joining Applied Genetic Technologies Corporation, Mr. Potter was employed by NeoStem, Inc., a developer of cell-based therapeutics, where he served as Executive Vice President from July 2013 to February 2015 and was a member of the Board of Directors from January 2013 to July 2013. Previously, Mr. Potter was Senior Vice President of Operations and Corporate Development for Osiris Therapeutics, Inc., from February 2011 to November 2012 where he was part of the senior leadership team that achieved approval of the first-ever stem cell drug therapy, Prochymal. He was also responsible for the launch and overall management of the Bio-Surgery business unit as well as operational oversight for multiple functional areas, including manufacturing, human resources, IT, legal and business development. From 2006 through 2010 Mr. Potter served as Senior Vice President of Corporate and Business Development at Genzyme Corporation and as Vice President of Corporate and Business Development. While at Genzyme, he was the senior leader for its global corporate and business development team that provided strategic and transaction support, including support for many of Genzyme's gene and cell therapy opportunities. Mr. Potter has also held positions at DuPont Pharmaceuticals, E.I. Dupont de Nemours and Company, Inc., and Booz Allen & Hamilton. Mr. Potter earned a B.S. from the University of Massachusetts and an MBA from Harvard Business School.- Stephen Potter，2015年1月起，担任本公司的副总裁、首席商业官。加入本公司之前，他任职于NeoStem, Inc.，这是基于细胞疗法的开发商；2013年7月至2015年2月，担任其执行副总裁；2013年1月至7月，担任董事。此前，2011年2月至2012年11月，他担任Osiris Therapeutics, Inc.的运营与企业发展高级副总裁，是史上首个获得审批的干细胞药物疗法Prochymal的高级领导团队成员；他还曾负责生物外科业务部门的组建和全面管理，并负责许多职能领域的业务监督，包括制造、人力资源、信息技术、法律、业务开发。2006-2010，他曾担任的Genzyme Corporation企业与业务开发高级副总裁，以及企业与业务开发副总裁；任职于该 公司期间，他曾是全球企业与业务开发团队的高级领导人，提供策略及交易支持，其中曾为公司的许多基因和细胞疗法业务提供支持。他还在下列公司担任过多个职务：DuPont Pharmaceuticals、E.I. Dupont de Nemours and Company, Inc.、Booz Allen & Hamilton。他在University of Massachusetts获得学士学位，在Harvard Business School获得工商管理硕士。
- Stephen Potter has served as Applied Genetic Technologies Corporation's Chief Business Officer since February 2015. Prior to joining Applied Genetic Technologies Corporation, Mr. Potter was employed by NeoStem, Inc., a developer of cell-based therapeutics, where he served as Executive Vice President from July 2013 to February 2015 and was a member of the Board of Directors from January 2013 to July 2013. Previously, Mr. Potter was Senior Vice President of Operations and Corporate Development for Osiris Therapeutics, Inc., from February 2011 to November 2012 where he was part of the senior leadership team that achieved approval of the first-ever stem cell drug therapy, Prochymal. He was also responsible for the launch and overall management of the Bio-Surgery business unit as well as operational oversight for multiple functional areas, including manufacturing, human resources, IT, legal and business development. From 2006 through 2010 Mr. Potter served as Senior Vice President of Corporate and Business Development at Genzyme Corporation and as Vice President of Corporate and Business Development. While at Genzyme, he was the senior leader for its global corporate and business development team that provided strategic and transaction support, including support for many of Genzyme's gene and cell therapy opportunities. Mr. Potter has also held positions at DuPont Pharmaceuticals, E.I. Dupont de Nemours and Company, Inc., and Booz Allen & Hamilton. Mr. Potter earned a B.S. from the University of Massachusetts and an MBA from Harvard Business School.
- Susan Schneider
Susan Schneider在生物技术公司拥有超过15年的执行和医疗专业经验，在多个疾病适应症的早期和后期眼科开发计划。从2020年9月到2021年10月，Schneider博士担任生物技术公司Ji Xing Pharmaceuticals眼科临床开发高级副总裁。在此之前，施耐德博士于2019年3月至2020年3月担任Eloxx Pharmaceuticals临床开发，眼科高级副总裁，Eloxx Pharmaceuticals是一家临床阶段的生物制药公司，开发新型RNA调节候选药物，她是Oxurion NV的首席医疗官，以前是Thrombogenics NV，从2017年11月到2018年11月，一家生物制药公司正在为患有影响眼球后部的疾病的患者开发保护视力的疗法。Schneider博士于2014年7月至2017年10月在制药公司Allergan plc工作，最初担任副总裁，负责治疗区域头部青光眼和湿性AMD直到2015年，然后担任副总裁和治疗区域头部青光眼和视网膜直到2017年10月。Schneider博士获得了宾夕法尼亚医学院的医学博士学位和宾夕法尼亚大学的文学学士学位。
Susan Schneider, M.D. has served as Applied Genetic Technologies Corporation's Chief Medical Officer since November 2021. Dr. Schneider has over fifteen years of experience as an executive and medical professional at biotechnology companies with early and late stage ophthalmic development programs in multiple disease indications. From September 2020 to October 2021 Dr. Schneider was Senior Vice President of Clinical Development, Ophthalmology at Ji Xing Pharmaceuticals, a biotechnology company. Prior to that, Dr. Schneider was Senior Vice President of Clinical Development, Ophthalmology at Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates, from March 2019 to March 2020 and she was Chief Medical Officer at Oxurion NV formerly ThromboGenics NV, a biopharmaceutical company developing treatments to preserve vision for patients with diseases affecting the back of the eye, from November 2017 to November 2018. Dr. Schneider worked at Allergan plc, a pharmaceutical company, from July 2014 through October 2017 first as Vice President, Therapeutic Area Head Glaucoma and Wet AMD until 2015 and then as Vice President and Therapeutic Area Head Glaucoma and Retina through October 2017. Dr. Schneider earned an M.D. from the Medical College of Pennsylvania and a B.A. from the University of Pennsylvania.- Susan Schneider在生物技术公司拥有超过15年的执行和医疗专业经验，在多个疾病适应症的早期和后期眼科开发计划。从2020年9月到2021年10月，Schneider博士担任生物技术公司Ji Xing Pharmaceuticals眼科临床开发高级副总裁。在此之前，施耐德博士于2019年3月至2020年3月担任Eloxx Pharmaceuticals临床开发，眼科高级副总裁，Eloxx Pharmaceuticals是一家临床阶段的生物制药公司，开发新型RNA调节候选药物，她是Oxurion NV的首席医疗官，以前是Thrombogenics NV，从2017年11月到2018年11月，一家生物制药公司正在为患有影响眼球后部的疾病的患者开发保护视力的疗法。Schneider博士于2014年7月至2017年10月在制药公司Allergan plc工作，最初担任副总裁，负责治疗区域头部青光眼和湿性AMD直到2015年，然后担任副总裁和治疗区域头部青光眼和视网膜直到2017年10月。Schneider博士获得了宾夕法尼亚医学院的医学博士学位和宾夕法尼亚大学的文学学士学位。
- Susan Schneider, M.D. has served as Applied Genetic Technologies Corporation's Chief Medical Officer since November 2021. Dr. Schneider has over fifteen years of experience as an executive and medical professional at biotechnology companies with early and late stage ophthalmic development programs in multiple disease indications. From September 2020 to October 2021 Dr. Schneider was Senior Vice President of Clinical Development, Ophthalmology at Ji Xing Pharmaceuticals, a biotechnology company. Prior to that, Dr. Schneider was Senior Vice President of Clinical Development, Ophthalmology at Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates, from March 2019 to March 2020 and she was Chief Medical Officer at Oxurion NV formerly ThromboGenics NV, a biopharmaceutical company developing treatments to preserve vision for patients with diseases affecting the back of the eye, from November 2017 to November 2018. Dr. Schneider worked at Allergan plc, a pharmaceutical company, from July 2014 through October 2017 first as Vice President, Therapeutic Area Head Glaucoma and Wet AMD until 2015 and then as Vice President and Therapeutic Area Head Glaucoma and Retina through October 2017. Dr. Schneider earned an M.D. from the Medical College of Pennsylvania and a B.A. from the University of Pennsylvania.
- Hope D'Oyley Gay
Hope D & amp；8217；Oyley Gay自2021年12月起担任Applied Genetic Technologies Corporation的总法律顾问。2019年5月至2021年12月，D & 8217；Oyley-Gay女士担任Spirovant Sciences的总法律顾问兼行政副总裁，负责监督临床前基因治疗公司的法律、合规和业务运营。2018年9月至2019年5月，她担任全球律师事务所Reed Smith LLP的法律顾问，为制药和新兴生命科学公司的业务发展交易提供支持。2016年4月至2019年5月，D & 8217；Oyley-Gay女士担任Militia Hill Ventures的常驻执行官，这是一家创建和建立生命科学公司的风险投资公司。在此之前，D & amp；8217；Oyley-Gay女士曾于2001年7月至2015年4月在GlaxoSmithKline plc（现为全球生物制药公司GSK plc）担任多个职位，包括2009年至2015年担任副总裁兼副总法律顾问，为全球业务发展交易提供法律支持，包括但不限于许可交易、共同开发合作、并购、共同推广协议和撤资。D & # 8217；Oyley-Gay女士获得了学士学位。特拉华大学和宾夕法尼亚大学法学院法学博士。
Hope D'Oyley Gay has served as Applied Genetic Technologies Corporation's General Counsel since December 2021. From May 2019 to December 2021 Ms. D'Oyley-Gay served as General Counsel and Vice President of Administration at Spirovant Sciences, where she oversaw legal, compliance and business operations for the pre-clinical gene therapy company. From September 2018 to May 2019 she was counsel at Reed Smith LLP, a global law firm, where she supported business development transactions for pharmaceutical and emerging life sciences companies. From April 2016 to May 2019 Ms. D'Oyley-Gay was Executive-in-Residence at Militia Hill Ventures, a venture firm that creates and builds life sciences companies. Prior to that, Ms. D'Oyley-Gay served in a variety of positions at GlaxoSmithKline plc now GSK plc, a global biopharma company, from July 2001 to April 2015 including as Vice President and Associate General Counsel from 2009 to 2015 where she provided legal support to business development transactions globally, including but not limited to, licensing transactions, co-development collaborations, mergers and acquisitions, co-promotion agreements and divestments. Ms. D'Oyley-Gay received a B.S. from the University of Delaware and a J.D. from the University of Pennsylvania Law School.- Hope D & amp；8217；Oyley Gay自2021年12月起担任Applied Genetic Technologies Corporation的总法律顾问。2019年5月至2021年12月，D & 8217；Oyley-Gay女士担任Spirovant Sciences的总法律顾问兼行政副总裁，负责监督临床前基因治疗公司的法律、合规和业务运营。2018年9月至2019年5月，她担任全球律师事务所Reed Smith LLP的法律顾问，为制药和新兴生命科学公司的业务发展交易提供支持。2016年4月至2019年5月，D & 8217；Oyley-Gay女士担任Militia Hill Ventures的常驻执行官，这是一家创建和建立生命科学公司的风险投资公司。在此之前，D & amp；8217；Oyley-Gay女士曾于2001年7月至2015年4月在GlaxoSmithKline plc（现为全球生物制药公司GSK plc）担任多个职位，包括2009年至2015年担任副总裁兼副总法律顾问，为全球业务发展交易提供法律支持，包括但不限于许可交易、共同开发合作、并购、共同推广协议和撤资。D & # 8217；Oyley-Gay女士获得了学士学位。特拉华大学和宾夕法尼亚大学法学院法学博士。
- Hope D'Oyley Gay has served as Applied Genetic Technologies Corporation's General Counsel since December 2021. From May 2019 to December 2021 Ms. D'Oyley-Gay served as General Counsel and Vice President of Administration at Spirovant Sciences, where she oversaw legal, compliance and business operations for the pre-clinical gene therapy company. From September 2018 to May 2019 she was counsel at Reed Smith LLP, a global law firm, where she supported business development transactions for pharmaceutical and emerging life sciences companies. From April 2016 to May 2019 Ms. D'Oyley-Gay was Executive-in-Residence at Militia Hill Ventures, a venture firm that creates and builds life sciences companies. Prior to that, Ms. D'Oyley-Gay served in a variety of positions at GlaxoSmithKline plc now GSK plc, a global biopharma company, from July 2001 to April 2015 including as Vice President and Associate General Counsel from 2009 to 2015 where she provided legal support to business development transactions globally, including but not limited to, licensing transactions, co-development collaborations, mergers and acquisitions, co-promotion agreements and divestments. Ms. D'Oyley-Gay received a B.S. from the University of Delaware and a J.D. from the University of Pennsylvania Law School.
- Abraham Scaria
Abraham Scaria博士自2021年12月起担任Applied Genetic Technologies Corporation的首席科学官。从2019年10月到2021年11月，Scaria博士担任IVERIC bio的高级副总裁兼首席科学官，这是一家生物制药公司，专注于发现和开发具有显着未满足医疗需求的视网膜疾病的治疗方法。在此之前，从2017年4月到2019年8月，Scaria博士担任生物技术公司Casebia Therapeutics的眼科副总裁。2015年12月至2017年4月，Scaria博士还担任制药行业公司赛诺菲健赞的基因治疗研究主管。Scaria博士获得了学士学位。和M.S.来自孟买大学，他的博士学位。来自印第安纳大学医学院。
Abraham Scaria, Ph.D. has served as Applied Genetic Technologies Corporation's Chief Scientific Officer since December 2021. From October 2019 through November 2021 Dr. Scaria was Senior Vice President and Chief Scientific Officer of Iveric Bio, a biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs. Prior to this, from April 2017 through August 2019 Dr. Scaria served as Vice President of Ophthalmology for Casebia Therapeutics, a biotech company. Dr. Scaria also served as head of gene therapy research at Sanofi Genzyme, a pharmaceutical industry company, from December 2015 through April 2017. Dr. Scaria received his B.S. and M.S. from University of Bombay, and his Ph.D. from Indiana University School of Medicine.- Abraham Scaria博士自2021年12月起担任Applied Genetic Technologies Corporation的首席科学官。从2019年10月到2021年11月，Scaria博士担任IVERIC bio的高级副总裁兼首席科学官，这是一家生物制药公司，专注于发现和开发具有显着未满足医疗需求的视网膜疾病的治疗方法。在此之前，从2017年4月到2019年8月，Scaria博士担任生物技术公司Casebia Therapeutics的眼科副总裁。2015年12月至2017年4月，Scaria博士还担任制药行业公司赛诺菲健赞的基因治疗研究主管。Scaria博士获得了学士学位。和M.S.来自孟买大学，他的博士学位。来自印第安纳大学医学院。
- Abraham Scaria, Ph.D. has served as Applied Genetic Technologies Corporation's Chief Scientific Officer since December 2021. From October 2019 through November 2021 Dr. Scaria was Senior Vice President and Chief Scientific Officer of Iveric Bio, a biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs. Prior to this, from April 2017 through August 2019 Dr. Scaria served as Vice President of Ophthalmology for Casebia Therapeutics, a biotech company. Dr. Scaria also served as head of gene therapy research at Sanofi Genzyme, a pharmaceutical industry company, from December 2015 through April 2017. Dr. Scaria received his B.S. and M.S. from University of Bombay, and his Ph.D. from Indiana University School of Medicine.
- Jonathan I. Lieber
Jonathan I. Lieber自2021年9月起担任Applied Genetic Technologies Corporation首席财务官。从2018年12月到2021年9月，Lieber先生担任生物技术融资和会计咨询公司Danforth Advisors的董事总经理。Lieber先生曾于2015年6月至2018年12月担任Histogenics Corporation的首席财务官，该公司是一家专注于开发恢复性细胞疗法的生物制药公司。在此之前，他于2014年1月至2015年6月担任Metamark Genetics，Inc.的高级副总裁兼首席财务官，Metamark Genetics，Inc.是一家专注于泌尿科的私营分子诊断公司。2012年9月至2013年9月，Lieber先生担任生命科学行业高价值耗材制造商和供应商Repligen Corporation的首席财务官和财务主管。2009年6月至2012年5月，Lieber先生担任Xcellerex，Inc.的首席财务官和财务主管，该公司是一家私营公司，从事为生物制药行业制造和销售资本设备和相关消耗品。自2020年6月以来，Lieber先生一直在专注于癌症的生物技术公司Salarius制药的董事会任职。Lieber先生获得了纽约大学斯特恩商学院的金融学工商管理硕士学位和理学学士学位。波士顿大学工商管理与金融学博士。
Jonathan I. Lieber has served as Applied Genetic Technologies Corporation's Chief Financial Officer since September 2021. From December 2018 through September 2021 Mr. Lieber was managing director of Danforth Advisors, a biotech financing and accounting advisory firm. Mr. Lieber previously served as Chief Financial Officer of Histogenics Corporation, a biopharmaceutical company focused on the development of restorative cell therapies, from June 2015 through December 2018. Prior to that, he was Senior Vice President and Chief Financial Officer of Metamark Genetics, Inc., a privately held, urology-focused, molecular diagnostics company, from January 2014 to June 2015. From September 2012 to September 2013 Mr. Lieber served as Chief Financial Officer and Treasurer of Repligen Corporation, a manufacturer and supplier of high-value consumables to the life sciences industry. From June 2009 to May 2012 Mr. Lieber served as Chief Financial Officer and Treasurer of Xcellerex, Inc., a privately-held company engaged in the manufacture and sale of capital equipment and related consumables to the biopharmaceutical industry. Since June 2020 Mr. Lieber has served on the board of directors of Salarius Pharmaceuticals, a cancer-focused biotechnology company. Mr. Lieber received an M.B.A. in finance from the Stern School of Business of New York University and a B.S. in business administration and finance from Boston University.- Jonathan I. Lieber自2021年9月起担任Applied Genetic Technologies Corporation首席财务官。从2018年12月到2021年9月，Lieber先生担任生物技术融资和会计咨询公司Danforth Advisors的董事总经理。Lieber先生曾于2015年6月至2018年12月担任Histogenics Corporation的首席财务官，该公司是一家专注于开发恢复性细胞疗法的生物制药公司。在此之前，他于2014年1月至2015年6月担任Metamark Genetics，Inc.的高级副总裁兼首席财务官，Metamark Genetics，Inc.是一家专注于泌尿科的私营分子诊断公司。2012年9月至2013年9月，Lieber先生担任生命科学行业高价值耗材制造商和供应商Repligen Corporation的首席财务官和财务主管。2009年6月至2012年5月，Lieber先生担任Xcellerex，Inc.的首席财务官和财务主管，该公司是一家私营公司，从事为生物制药行业制造和销售资本设备和相关消耗品。自2020年6月以来，Lieber先生一直在专注于癌症的生物技术公司Salarius制药的董事会任职。Lieber先生获得了纽约大学斯特恩商学院的金融学工商管理硕士学位和理学学士学位。波士顿大学工商管理与金融学博士。
- Jonathan I. Lieber has served as Applied Genetic Technologies Corporation's Chief Financial Officer since September 2021. From December 2018 through September 2021 Mr. Lieber was managing director of Danforth Advisors, a biotech financing and accounting advisory firm. Mr. Lieber previously served as Chief Financial Officer of Histogenics Corporation, a biopharmaceutical company focused on the development of restorative cell therapies, from June 2015 through December 2018. Prior to that, he was Senior Vice President and Chief Financial Officer of Metamark Genetics, Inc., a privately held, urology-focused, molecular diagnostics company, from January 2014 to June 2015. From September 2012 to September 2013 Mr. Lieber served as Chief Financial Officer and Treasurer of Repligen Corporation, a manufacturer and supplier of high-value consumables to the life sciences industry. From June 2009 to May 2012 Mr. Lieber served as Chief Financial Officer and Treasurer of Xcellerex, Inc., a privately-held company engaged in the manufacture and sale of capital equipment and related consumables to the biopharmaceutical industry. Since June 2020 Mr. Lieber has served on the board of directors of Salarius Pharmaceuticals, a cancer-focused biotechnology company. Mr. Lieber received an M.B.A. in finance from the Stern School of Business of New York University and a B.S. in business administration and finance from Boston University.
- Susan B. Washer
Susan B. Washer，从2002年3月开始担任公司总裁兼CEO，2003年起担任董事。在成为总裁和CEO以前，她于2001年10月至2002年3月间担任公司首席运营官。1996年8月-2001年10月，她任Scenic Productions公司裁兼CEO，该公司是一家专业建筑公司，为娱乐产业提供雕刻、涂漆和建设服务。1994年6月至1996年8月，她担任北佛罗里达技术创新中心创始执行董事，后担任商业顾问， 该公司是一家公私合营机构，为创业公司提供通过佛罗里达州一些大学批准的技术服务。1983年10月至1994年6月，她在雅培公司和礼来制药厂担任过各种研发和药物管理职位。她拥有密歇根州立大学生物化学学士和佛罗里达大学工商管理硕士学位。
Susan B. Washer has served as Applied Genetic Technologies Corporation's President and Chief Executive Officer since March 2002 and as a member of Applied Genetic Technologies Corporation's board of directors since November 2003. Prior to becoming Applied Genetic Technologies Corporation's President and Chief Executive Officer, Ms. Washer served as Applied Genetic Technologies Corporation's Chief Operating Officer from October 2001 to March 2002. From August 1996 to October 2001 Ms. Washer was President and Chief Executive Officer of Scenic Productions Inc., a specialty construction firm providing sculpting, painting and construction services to the entertainment industry. From June 1994 to August 1996 Ms. Washer served as the Founding Executive Director and then Business Advisor for the North Florida Technology Innovation Center, a public-private organization financing and providing services to entrepreneurial companies licensing technology from Florida universities. From October 1983 to June 1994 Ms. Washer served in various research and pharmaceutical management positions with Abbott Laboratories and Eli Lilly and Company. Ms. Washer also served on the board of Histogenics Corporation from April 2018 to September 2019. In addition, Ms. Washer serves on several biotechnology industry related boards and committees, including as an appointed member of the Small Business Capital Formation Advisory Committee for the Securities and Exchange Commission, the Associate Vice President of the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization "BIO", and a member of the Board of Directors of each of BIO and BioFlorida. Ms. Washer received a B.S. in biochemistry from Michigan State University and an M.B.A. from the University of Florida.- Susan B. Washer，从2002年3月开始担任公司总裁兼CEO，2003年起担任董事。在成为总裁和CEO以前，她于2001年10月至2002年3月间担任公司首席运营官。1996年8月-2001年10月，她任Scenic Productions公司裁兼CEO，该公司是一家专业建筑公司，为娱乐产业提供雕刻、涂漆和建设服务。1994年6月至1996年8月，她担任北佛罗里达技术创新中心创始执行董事，后担任商业顾问， 该公司是一家公私合营机构，为创业公司提供通过佛罗里达州一些大学批准的技术服务。1983年10月至1994年6月，她在雅培公司和礼来制药厂担任过各种研发和药物管理职位。她拥有密歇根州立大学生物化学学士和佛罗里达大学工商管理硕士学位。
- Susan B. Washer has served as Applied Genetic Technologies Corporation's President and Chief Executive Officer since March 2002 and as a member of Applied Genetic Technologies Corporation's board of directors since November 2003. Prior to becoming Applied Genetic Technologies Corporation's President and Chief Executive Officer, Ms. Washer served as Applied Genetic Technologies Corporation's Chief Operating Officer from October 2001 to March 2002. From August 1996 to October 2001 Ms. Washer was President and Chief Executive Officer of Scenic Productions Inc., a specialty construction firm providing sculpting, painting and construction services to the entertainment industry. From June 1994 to August 1996 Ms. Washer served as the Founding Executive Director and then Business Advisor for the North Florida Technology Innovation Center, a public-private organization financing and providing services to entrepreneurial companies licensing technology from Florida universities. From October 1983 to June 1994 Ms. Washer served in various research and pharmaceutical management positions with Abbott Laboratories and Eli Lilly and Company. Ms. Washer also served on the board of Histogenics Corporation from April 2018 to September 2019. In addition, Ms. Washer serves on several biotechnology industry related boards and committees, including as an appointed member of the Small Business Capital Formation Advisory Committee for the Securities and Exchange Commission, the Associate Vice President of the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization "BIO", and a member of the Board of Directors of each of BIO and BioFlorida. Ms. Washer received a B.S. in biochemistry from Michigan State University and an M.B.A. from the University of Florida.